Woods S W, Nagy L M, Koleszar A S, Krystal J H, Heninger G R, Charney D S
Yale University, Department of Psychiatry, New Haven, CT 06519.
J Clin Psychopharmacol. 1992 Feb;12(1):32-8. doi: 10.1097/00001573-199202000-00006.
To investigate whether alprazolam (ALP) coprescription early in the imipramine (IMI) treatment of panic disorder would improve overall treatment response to IMI alone, 48 panic disorder patients were randomly assigned to receive either IMI plus placebo or IMI plus ALP for 4-6 weeks, followed by 2 weeks of IMI plus placebo-ALP taper and 2 more weeks of IMI alone. Although patients in the IMI plus ALP group improved more quickly, significantly more patients in the IMI plus ALP group could not follow the taper schedule. The results suggest that studies employing other benzodiazepines or other ALP dosage or taper schedules would be required to demonstrate any benefit for the IMI plus early benzodiazepine cotreatment strategy over IMI alone in the routine pharmacologic management of panic disorder.
为了研究在惊恐障碍患者接受丙咪嗪（IMI）治疗早期联合使用阿普唑仑（ALP）是否会改善单独使用IMI的总体治疗反应，48名惊恐障碍患者被随机分配接受IMI加安慰剂或IMI加ALP治疗4 - 6周，随后2周逐渐减少IMI加安慰剂 - ALP剂量，并再单独使用2周IMI。虽然IMI加ALP组的患者改善更快，但IMI加ALP组中有更多患者无法遵循逐渐减量计划。结果表明，在惊恐障碍的常规药物治疗中，需要采用其他苯二氮䓬类药物、其他ALP剂量或逐渐减量计划的研究，以证明IMI联合早期苯二氮䓬类药物联合治疗策略相对于单独使用IMI有任何益处。
